Fortrea HoldingsMEX:FTRE1 66 EBITDA Margin % is 4.18% as of Mar. 2026, which is 38% below its 10-year median of 6.71. GuruFocus rates MEX:FTRE1 with a GF Score™ of 66/100 and a GF Value™ of MXN450.34. The stock has 7 warning signs investors should review. Among 944 Biotechnology companies, Fortrea Holdings ranks better than 62.71% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Fortrea Holdings's EBITDA for the
three
months ended in Mar. 2026 was MXN480 Mil. Fortrea Holdings's Revenue for the
three
months ended in Mar. 2026 was MXN11,478 Mil. Therefore, Fortrea Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 4.18%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Fortrea Holdings EBITDA Margin % Related Terms
Fortrea Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Fortrea Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:FTRE1 vs MAZE, KALV, BCAX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Fortrea Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortrea Holdings EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortrea Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Fortrea Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortrea Holdings (MEX:FTRE1) has a EBITDA Margin % of 4.18% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fortrea Holdings and its competitors. This is 38% below median its historical median of 6.71. According to the industry distribution chart, Fortrea Holdings ranks #352 out of 944 companies in the Biotechnology industry, placing it in the top 37.3%.
Is Fortrea Holdings' EBITDA Margin % too high?
Fortrea Holdings' current EBITDA Margin % of 4.18% is 38% below median its 10-year median of 6.71. Based on the distribution chart, Fortrea Holdings ranks #352 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fortrea Holdings has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Fortrea Holdings' EBITDA Margin % compare to MAZE and KALV?
According to the Biotechnology industry distribution chart, Fortrea Holdings ranks #352 out of 944 companies for EBITDA Margin %. This puts Fortrea Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fortrea Holdings and its competitors. Fortrea Holdings's current EBITDA Margin % is 4.18%, which is 38% below median its own 10-year median of 6.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortrea Holdings stock overvalued right now?
Fortrea Holdings (MEX:FTRE1) has a current EBITDA Margin % of 4.18%. The stock's GF Value™ is MXN450.34, compared to a current price of MXN435.30 — trading 3.3% below its estimated fair value. The current EBITDA Margin % is 4.18%, which is 38% below median its 10-year median of 6.71. Fortrea Holdings' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Fortrea Holdings (MEX:FTRE1), the current EBITDA Margin % is 4.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortrea Holdings (MEX:FTRE1) Overvalued in 2026?
Based on GuruFocus' analysis, Fortrea Holdings stock appears to be undervalued.
The current stock price of MXN435.30 is trading 3.3% below its estimated GF Value™ of MXN450.34.
Key valuation signals for MEX:FTRE1:
EBITDA Margin %: 4.18% (38% below median its 10-year median of 6.71)
GF Value™: MXN450.34 vs. price of MXN435.30 (3.3% below fair value)
No single metric tells the full story. See the MEX:FTRE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
66GF Score
Get the complete analysis for MEX:FTRE1
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:FTRE1 has been successfully added to your 
